Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nolazol in adults with ADHD
NCT02808104Phase 2Completed
- Sponsor
- NLS Pharmaceutics AG
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Mazindol ER in attention deficit hyperactivity disorder (ADHD), sponsored by NLS Pharmaceutics AG. Started Aug 2016; status: completed.
02
Drugs
Mazindol ER
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02808104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808104.